Search - tctmd.com

Displaying 341 - 360 of 598

Sort: Relevancy | Date

News Daily News

Surgical Bailout Rarely Needed Though Can Save Lives: TVT Registry

Yael L. Maxwell

September 18, 2019

News Daily News

VA Medical Centers’ Quality Measures for TAVR Pay Off

Caitlin E. Cox

August 30, 2019

News Daily News

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

Caitlin E. Cox

August 27, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Daily News

Life Expectancy Post-SAVR Varies by Age, Raising Questions for Treatment Timing

Caitlin E. Cox

July 01, 2019

News Daily News

New TAVR NCD a ‘Missed Opportunity’ to Align SAVR, TAVR Quality

Shelley Wood

June 27, 2019

News Daily News

CMS Releases Final Decision Memo on Rules for TAVR Program Reimbursement

Shelley Wood

June 24, 2019

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Michael O'Riordan

June 17, 2019

News Conference News TVT 2019

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

Shelley Wood

June 13, 2019

Presentation TVT 2019

The Next TAVR vs. SAVR Randomized Trial Should Be in Patients With Bicuspid Aortic Valves

Presenter: Raj Makkar

June 13, 2019

Presentation TVT 2019

Do We Need a Randomized Trial of VIV vs. Redo SAVR for Failed Bioprosthetic Surgical Valves? The REPEAT Trial

Presenter: Vinayak Bapat

June 13, 2019

News Daily News

TAVR Growing in the US, but Vast Majority of Patients Not Receiving Any Form of Valve Replacement

Michael O'Riordan

June 12, 2019

News Conference News EuroPCR 2019

Endocarditis After TAVR: Real-world Data Speak to Its Rarity but Also the ‘Devastating’ Impact

Caitlin E. Cox

June 07, 2019

News Conference News SCAI 2019

TAVR Operators: Can One Do It All or Are Two Still Justified?

Yael L. Maxwell

June 04, 2019

News Conference News EuroPCR 2019

TAVR Durability ‘Snapshot’ Offers Some Reassurances 8 to 10 Years Out

Caitlin E. Cox

May 24, 2019

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Shelley Wood

May 23, 2019

Advertisement

Surgical Bailout Rarely Needed Though Can Save Lives: TVT Registry

VA Medical Centers’ Quality Measures for TAVR Pay Off

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

FDA Expands TAVR Indication to Low-Risk Patients

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

TCTMD’s Top 10 Most Popular Stories for July 2019

Life Expectancy Post-SAVR Varies by Age, Raising Questions for Treatment Timing

New TAVR NCD a ‘Missed Opportunity’ to Align SAVR, TAVR Quality

CMS Releases Final Decision Memo on Rules for TAVR Program Reimbursement

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

The Next TAVR vs. SAVR Randomized Trial Should Be in Patients With Bicuspid Aortic Valves

Do We Need a Randomized Trial of VIV vs. Redo SAVR for Failed Bioprosthetic Surgical Valves? The REPEAT Trial

TAVR Growing in the US, but Vast Majority of Patients Not Receiving Any Form of Valve Replacement

Endocarditis After TAVR: Real-world Data Speak to Its Rarity but Also the ‘Devastating’ Impact

TAVR Operators: Can One Do It All or Are Two Still Justified?

TAVR Durability ‘Snapshot’ Offers Some Reassurances 8 to 10 Years Out

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content